AstraZeneca has announced a $3.5 billion capital investment in the United States to expand its research and manufacturing capabilities by the end of 2026. The investment includes $2 billion in new funding that will create over 1,000 high-skilled jobs, focusing on establishing a state-of-the-art R&D center in Cambridge, Massachusetts, next-generation biologics facility in Maryland, cell therapy manufacturing on both coasts, and specialty manufacturing in Texas.The investment aligns with AstraZeneca's Ambition 2030 strategy to achieve $80 billion in Total Revenue by 2030, with particular emphasis on accelerating development in the United States, which currently generates 44% of the company's total revenue. The company maintains a significant US presence with approximately 17,800 employees across 17 R&D, manufacturing, and commercial sites in 12 states.

AstraZeneca has announced a $3.5 billion capital investment in the United States to expand its research and manufacturing capabilities by the end of 2026. The investment includes $2 billion in new funding that will create over 1,000 high-skilled jobs, focusing on establishing a state-of-the-art R&D center in Cambridge, Massachusetts, next-generation biologics facility in Maryland, cell therapy manufacturing on both coasts, and specialty manufacturing in Texas.The investment aligns with AstraZeneca's Ambition 2030 strategy to achieve $80 billion in Total Revenue by 2030, with particular emphasis on accelerating development in the United States, which currently generates 44% of the company's total revenue. The company maintains a significant US presence with approximately 17,800 employees across 17 R&D, manufacturing, and commercial sites in 12 states.